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Abstracts

Psychopathology, self-esteem, and self-perceived stigma
were also measured using the Positive and Negative Syndrome Scale, the Rosenberg Self-Esteem Scale (SES), the Beck
Depression Inventory (BDI), the Beck Hopelessness Scale, and
the Korean version of the Internalized Stigma of Mental Illness scale (K-ISMI).
Results
- Of the total of 87 participants, 20 (23%) had attempted suicide.
Patients with a history of suicide attempts had significantly
higher scores on the BDI (p=0.036) and K-ISMI (p=0.009), and
significantly lower scores on the SES (p=0.001). Analysis of
covariance revealed that the SES scores were significantly
lower in patients with a history of previous suicide attempts
than in those with no history, after controlling for K-ISMI and
BDI scores (p = 0.039).
Conclusion
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Abstract
Background: Second-generation antipsychotics (SGAs), such
as olanzapine, are used to treat schizophrenia; however, they
have minimal benefits for cognitive deficits and cause metabolic side-effects such as obesity [1, 2]. Obesity has been linked
to increased cognitive impairment [3], complicating the health
issues of people with schizophrenia. Liraglutide is a synthetic
glucagon-like peptide-1 (GLP-1) receptor agonist with antiobesity and neuroprotective properties [4, 5]; however, whether
liraglutide can improve cognition during olanzapine treatment
is unclear. The aim of this study was to examine the effects of
liraglutide co-treatment on cognition and metabolic parameters
during olanzapine treatment.
Methods: Sprague-Dawley rats were administered olanzapine (2mg/kg), liraglutide (0.4mg/kg), olanzapine+liraglutide cotreatment or vehicle (control) (n=12/group) for six weeks. Body
weight, food intake and locomotor activity were recorded. Novel
object recognition (NOR) and T-maze tests were conducted to
examine recognition and working memory. Post-mortem white
adipose tissue weight was recorded.
Results: Olanzapine caused significant body weight gain and
increased white adipose tissue mass (p<0.05 vs control), whereas
liraglutide co-treatment significantly reduced body weight and
adiposity (p<0.001 vs olanzapine). Olanzapine induced hypolocomotion (p<0.001 vs control), whereas liraglutide co-treatment
significantly increased locomotor activity (p<0.05 vs olanzapine). In the NOR test, olanzapine-treated rats spent significantly
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less time exploring the novel object, and this was significantly
improved in the liraglutide co-treatment group (p<0.01 vs olanzapine). There was no effect of treatment on correct entries in
the T-maze test (p>0.05 vs control).
Conclusion: This study demonstrates that liraglutide co-treatment can improve locomotor activity, decrease adiposity and
prevent weight gain side-effects associated with olanzapine
administration. Liraglutide co-treatment was able to improve
recognition memory impairment caused by olanzapine treatment; however, it had no effect on working memory. Further
studies are required to understand the mechanisms underlying
these changes, and to elucidate whether a link exists between
olanzapine-induced obesity and liraglutide’s effect on cognition.
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Abstract
Objective: Clozapine is the most effective antipsychotic for
treatment-resistant schizophrenia, whereas it occurs fatal
hematopoietic toxicity as agranulocytosis. To elucidate mechanism of hematopoietic toxicity by clozapine, we tried to develop
the in vitro assay systems using HL-60 cells, and investigated the
effect on hematopoiesis.
Method: HL-60 cells were differentiated by all-trans retinoic acid
(ATRA) to three states according hematopoietic process: undifferentiated HL-60 cells, under granulocytic ATRA-differentiation
and ATRA-differentiated granulocytic cells. Hematopoietic toxicity was evaluated by analyzing cell survival, cell proliferation,
granulocytic differentiation, apoptosis, and necrosis.
Result: In undifferentiated HL-60 cells and ATRA-differentiated
granulocytic cells, clozapine (50 and 100 µM) and doxorubicin,
but not olanzapine decreased survival rate. Under granulocytic
differentiation for 5 days, clozapine, even at 25 µM, decreased
survival rate without affecting granulocytic differentiation,
increased caspase activity, and resulted in induction of apoptosis rather than necrosis. Lower concentrations of clozapine (1
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- Low self-esteem appears to represent a psychological dimension that is closely related to suicide risk. Therefore, clinical
attention should be paid to the evaluation and enhancement
of low self-esteem in schizophrenia patients with suicidality. A longitudinal prospective study is required to ascertain
whether low self-esteem leads suicide attempts.
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